The epidemiological effect and cost-effectiveness of expanded age eligibility for recombinant zoster vaccination in England
Providing one or two doses of RZV for older adults can be cost-effective and would reduce the healthcare burden of shingles.
Authors
- Nicholas Davies (ORCID: https://orcid.org/0000-0003-4095-4549)
- Koen B. Pouwels (ORCID: https://orcid.org/0000-0001-7097-8950)
- Chu-Chang Ku
- Jemma Walker
- Alicia Rosello
- Mark Jit
- Marc Baguelin
Institutions
- University of London (GB)
- Animal and Plant Health Agency (GB)
- University of Oxford (GB)
- London School of Hygiene & Tropical Medicine (GB)
Publication Details
- Journal
- Vaccine
- Published
- 2026-03-04
- DOI
- https://doi.org/10.1016/j.vaccine.2026.128405
- Primary Topic
- Herpesvirus Infections and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institute for Health Research Health Protection Research Unit
- National Institute for Health and Care Research